p53, bcl-2 and retinoblastoma proteins as long-term prognostic markers in localized carcinoma of the prostate

Journal of Urology

Volumn 158, Issue 1, 1997, Pages 131-137

  Theodorescu, Dan ^a,b   Broder, Stanford R ^a   Boyd, James C ^a   Mills, Stacey E ^a   Frierson Jr , Henry F ^a  

^a UNIVERSITY OF VIRGINIA HEALTH SYSTEM   (United States)

^b UNIVERSITY OF VIRGINIA   (United States)

Author keywords

Biological; Prostatic neoplasms; Protein p53; Retinoblastoma protein; Tumor markers

Indexed keywords

GENE PRODUCT; PROTEIN P53; RETINOBLASTOMA PROTEIN; TUMOR MARKER;

ADULT; AGED; ARTICLE; CANCER INVASION; CANCER STAGING; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOCOMPETENT CELL; MAJOR CLINICAL STUDY; MALE; MOLECULAR CLONING; MULTIVARIATE ANALYSIS; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; PROSPECTIVE STUDY; PROSTATE CANCER; PROSTATECTOMY; TREATMENT PLANNING; TUMOR LOCALIZATION;

EID: 0030967596     PISSN: 00225347     EISSN: None     Source Type: Journal    
DOI: 10.1097/00005392-199707000-00040     Document Type: Article

References (40)

1. Epstein, J. I.: Pathology of prostatic intraepithelial neoplasia and adenocarcinoma of the prostate: prognostic influences of stage, tumor volume, grade, and margins of resection. Sem. Oncol., 21: 527, 1994.
2. Epstein, J. I., Walsh, P. C. and Brendler, C. B.: Radical prostatectomy for impalpable prostate cancer: the Johns Hopkins experience with tumors found on transurethral resection (stages T1A and T1B) and on needle biopsy (stage T1C). J. Urol., 152: 1721, 1994.
3. Ohori, M., Wheeler, T. M., Dunn, J. K., Stamey, T. A. and Scardino, P. T.: The pathological features and prognosis of prostate cancer detectable with current diagnostic tests. J. Urol., 152: 1714, 1994.
4. Catalona, W. J., Smith, D. S., Ratliff, T. L. and Basler, J. W.: Detection of organ-confined prostate cancer is increased through prostate-specific antigen-based screening. J.A.M.A., 270: 948, 1993.
5. Takayama, T. K., Vessella, R. L. and Lange, P. H.: Newer applications of serum prostate-specific antigen in the management of prostate cancer. Sem. Oncol., 21: 542, 1994.
6. Catalona, W. J. and Smith, D. S.: 5-year tumor recurrence rates after anatomical radical retropubic prostatectomy for prostate cancer. J. Urol., 152: 1837, 1994.
7. Ellis, W. J. and Lange, P. H.: Prostate cancer. Endocr. Metab. Clin. N. Amer., 23: 809, 1994.
8. Whittemore, A. S., Keller, J. B. and Betensky, R.: Low-grade, latent prostate cancer volume: predictor of clinical cancer incidence? J. Nat. Cancer Inst., 83: 1231, 1991.
9. Stamey, T. A., Freiha, F. S., McNeal, J. E., Redwine, E. A., Whittemore, A. S. and Schmid, H.-P.: Localized prostate cancer: relationship of tumor volume to clinical significance for treatment of prostate cancer. Cancer, suppl., 71: 933, 1993.
10. Shurbaji, M. S., Kalbfleisch, J. H. and Thurmond, T. S.: Immunohistochemical detection of p53 protein as a prognostic indicator in prostate cancer. Hum. Path., 26: 106, 1995.
11. Ittmann, M., Wieczorek, R., Heller, P., Dave, A., Provet, J. and Krolewski, J.: Alterations in the p53 and MDM-2 genes are infrequent in clinically localized, stage B prostate adenocarcinomas. Amer. J. Path., 145: 287, 1994.
12. Aprikian, A. G., Sarkis, A. S., Fair, W. R., Zhang, Z.-F., Fuks, Z. and Cordon-Cardo, C.: Immunohistochemical determination of p53 protein nuclear accumulation in prostatic adenocarcinoma. J. Urol., 151: 1276, 1994.
13. Kallakury, B. V., Figge, J., Ross, J. S., Fisher, H. A., Figge, H. L. and Jennings, T. A.: Association of p53 immunoreactivity with high Gleason tumor grade in prostatic adenocarcinoma. Hum. Path., 25: 92, 1994.
14. Thomas, D. J., Robinson, M., King, P., Hasan, T., Charlton, R., Martin, J., Carr, T. W. and Neal, D. E.: p53 expression and clinical outcome in prostate cancer. Brit. J. Urol., 72: 778, 1993.
15. Navone, N. M., Troncoso, P., Pisters, L. L., Goodrow, T. L., Palmer, J. L., Nichols, W. W., von Eschenbach, A. C. and Conti, C. J.: p53 accumulation and gene mutation in the progression of human prostate carcinoma. J. Nat. Cancer Inst., 85: 1657, 1993.
16. Bookstein, R., MacGrogan, D., Hilsenbeck, S. G., Sharkey, F. and Allred, D. C.: p53 is mutated in a subset of advanced-stage prostate cancers. Cancer Res., 53: 3369, 1993.
17. Effert, P. J., McCoy, R. H., Walther, P. J. and Liu, E. T.: p53 gene alterations in human prostate carcinoma. J. Urol., 150: 257, 1993.
18. Van Veldhuizen, P. J., Sadasivan, R., Garcia, F., Austenfeld, M. S. and Stephens, R. L.: Mutant p53 expression in prostate carcinoma. Prostate, 22: 23, 1993.
19. Thompson, S. J., Mellon, K., Charlton, R. G., Marsh, C., Robinson, M. and Neal, D. E.: P53 and Ki-67 immunoreactivity in human prostate cancer and benign hyperplasia. Brit. J. Urol., 69: 609, 1992.
20. Phillips, S. M., Barton, C. M., Lee, S. J., Morton, D. G., Wallace, D. M., Lemoine, N. R. and Neoptolemos, J. P.: Loss of the retinoblastoma susceptibility gene (RB1) is a frequent and early event in prostatic tumorigenesis. Brit. J. Cancer, 70: 1252, 1994.
21. Brooks, J. D., Bova, G. S. and Isaacs, W. B.: Allelic loss of the retinoblastoma gene in primary human prostatic adenocarcinomas. Prostate, 26: 35, 1995.
22. Colombel, M., Symmans, F., Gil, S., O'Toole, K. M., Chopin, D., Benson, M., Olsson, C. A., Korsmeyer, S. and Buttyan, R.: Detection of the apoptosis-suppressing oncoprotein bcl-2 in hormone-refractory human prostate cancers. Amer. J. Path., 143: 390, 1993.
23. McDonnell, T. J., Troncoso, P., Brisbay, S. M., Logothetis, C., Chung, L. W., Hsieh, J. T., Tu, S. M. and Campbell, M. L.: Expression of the protooncogene bcl-2 in the prostate and its association with emergence of androgen-independent prostate cancer. Cancer Res., 52: 6940, 1992.
24. Mills, S. E. and Fowler, J. E., Jr.: Gleason histologic grading of prostatic carcinoma. Correlations between biopsy and prostatectomy specimens. Cancer, 57: 346, 1986.
25. Prioleau, J. and Schnitt, S. J.: p53 antigen loss in stored paraffin slides. New Engl. J. Med., 332: 1521, 1995.
26. Humphrey, P. A. and Vollmer, R. T.: Intraglandular tumor extent and prognosis in prostatic carcinoma: application of a grid method to prostatectomy specimens. Hum. Path., 21: 799, 1990.
27. Cox, D. R.: Partial likelihood. Biometrika, 62: 269, 1975.
28. Cox, D. R.: Regression models and life tables (with discussion). J. Roy. Stat. Soc., 34: 187, 1972.
29. Furnival, G. M. and Wilson, R. W.: Regression by leaps and bounds. Technometrics, 16: 499, 1974.
30. Rao, C. R.: Linear Statistical Inference and its Applications, 2nd ed. New York: Wiley, 1973.
31. Kaplan, E. L. and Meier, P.: Nonparametric estimation from incomplete observations. J. Amer. Stat. Ass., 53: 457, 1958.
32. Peto, R., Pike, M. C., Armitage, P., Breslow, N. E., Cox, D. R., Howard, S. V., Mantel, N., McPherson, K., Peto, J. and Smith, P. G.: Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. Analysis and examples. Brit. J. Cancer, 35: 1, 1977.
33. Esrig, D., Elmajian, D., Groshen, S., Freeman, J. A., Stein, J. P., Chen, S. C., Nichols, P. W., Skinner, D. G., Jones, P. A. and Cote, R. J.: Accumulation of nuclear p53 and tumor progression in bladder cancer. New Engl. J. Med., 331: 1259, 1994.
34. Karpeh, M. S., Brennan, M. F., Cance, W. G., Woodruff, J. M., Pollack, D., Casper, E. S., Dudas, M. E., Latres, E., Drobnjak, M. and Cordon-Cardo, C.: Altered patterns of retinoblastoma gene product expression in adult soft-tissue sarcomas. Brit. J. Cancer, 72: 986, 1995.
35. Lipponen, P. K. and Liukkonen, T. J.: Reduced expression of retinoblastoma (Rb) gene protein is related to cell proliferation and prognosis in transitional-cell bladder cancer. J. Cancer Res. Clin. Oncol., 121: 44, 1995.
36. Wingo, P. A., Tong, T. and Bolden, S.: Cancer statistics, 1995. CA, 45: 8, 1995.
37. Smith, D. S. and Catalona, W. J.: The nature of prostate cancer detected through prostate specific antigen based screening. J. Urol., 152: 1732, 1994.
38. Brawer, M. K., Beatie, J., Wener, M. H., Vessella, R. L., Preston, S. D. and Lange, P. H.: Screening for prostatic carcinoma with prostate specific antigen: results of the second year. J. Urol., 150: 106, 1993.
39. Partin, A. W., Pound, C. P., Clemens, J. Q., Epstein, J. I. and Walsh, P. C.: Serum PSA after anatomic radical prostatectomy. Urol. Clin. N. Amer., 20: 713, 1993.
40. Partin, A. W., Yoo, J., Carter, H. B., Pearson, J. D., Chan, D. W., Epstein, J. I. and Walsh, P. C.: The use of prostate specific antigen, clinical stage and Gleason score to predict pathological stage in men with localized prostate cancer. J. Urol., 150: 110, 1993.